June 17, 2008

Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical

SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today their accreditation as an Exemplary Provider for Medicare beneficiaries. The Medicare Modernization Act requires that all DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, Supplies) providers who participate in the Medicare program must be successfully accredited.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Receiving Medicare accreditation is a significant step for Regenesis as we expand the availability of Provant to more Medicare and Medicaid patients," said Virginia Rybski, Acting President of Regenesis. "Our organization's core values parallel Medicare's accreditation quality standards for adhering to ethical business procedures. To earn Exemplary Provider certification, we demonstrated outstanding healthcare delivery practices and compliance to safety, honesty, and compassionate care for our patients and service to clinicians and administrators."

Regenesis' core values include: having a pioneering spirit in the development of new regenerative medical products, striving for excellence in all business aspects, having respect for all people, living and working as a family unified in a common goal, applying integrity in our decision making processes, having compassion for all people, especially our patients, and dedication to improving the lives of all whom we encounter.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

    Contact:    Regenesis Biomedical, Inc.    Media:       Scott Robey, VP Marketing, [email protected]    Clinicians:  Rick Isenberg, MD, VP Clinical Affairs,                 [email protected]    Investors:   Virginia Rybski, Acting President,                 [email protected]    http://www.regenesisbiomedical.com/    480-970-4970  

Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008AP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

Regenesis Biomedical, Inc.

CONTACT: media, Scott Robey, VP Marketing,[email protected], or clinicians, Rick Isenberg, MD, VP ClinicalAffairs, [email protected], or investors, Virginia Rybski,Acting President, [email protected], all of Regenesis Biomedical,Inc., +1-480-970-4970

Web site: http://www.regenesisbiomedical.com/